**Significant client savings. Clinically appropriate coverage**

Good Morning,

CVS Caremark® and Aetna® strive to help you control drug spend without compromising care. To do this in an ever-changing market, we must remain agile. We have a strong history of studying the market and evolving our model to help you stay one step ahead.

**Fueling benefits with biosimilars**

Generic medications transformed the pharmacy landscape and biosimilars (FDA approved biologic medications that are highly similar to, and have no clinically meaningful differences from, a biologic medicine already approved by the FDA) have the power to do the same. Supporting the adoption of – and easier access to – biosimilars will be critical to increasing competition and lowering specialty drug costs while improving affordability for members.

Effective April 1, 2024, Humira (adalimumab) will be removed from many of our commercial formularies. While this creates a need for many members to make a change to a preferred biosimilar or other preferred product, they will continue to have access to adalimumab (the same molecule), through biosimilar products that are safe, effective, easy to use and have predictable availability. Please refer to the chart we provided regarding these formulary changes at the end of this letter.

Our biosimilar-focused formulary strategy is projected to save up to 27 percent in net costs within the autoimmune class compared to 2022.

**Using clinical rigor to evaluate biosimilars**

The preferred products on the template formularies provide all the important attributes to ensure clinically appropriate coverage for the broad range of plan members that need therapy.

**Robust member and prescriber support for a smooth transition**

Using digital tools and electronic health record (EHR) connectivity, we can meaningfully engage prescribers well in advance of a formulary change to guide them through appropriate next steps and deliver an exceptional experience for members.

Historically, more than 94 percent of members have adopted preferred biosimilar products in specialty categories.2 With a clinically sound formulary strategy that prefers biosimilars coupled with a seamless transition plan, we will deliver significant savings to you and your members.

Please do not hesitate to reach out with questions. We are here to help you balance cost and care in a rapidly changing health care landscape.

**Thank you,**

**Penny Pollard, Account Manager**

**Aetna Commercial Formulary Strategy Effective April 1, 2024**

**Fully Insured plan sponsors**

|  |  |  |
| --- | --- | --- |
| **Commercial Formularies – Insured** | | |
| Advanced Control Plan-Aetna | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |
| Standard Opt Out-Aetna | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |

**Self-funded plan sponsors with impacted formulary change**

|  |  |  |
| --- | --- | --- |
| **Formulary** | **Preferred Biosimilar and Reference Brand Options** | **Other Preferred Options\*** |
| **Commercial Formularies – Self-Funded** | | |
| Advanced Control Plan | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |
| Aetna Standard Plan | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |
| Basic Control Plan    and    Basic Control Plan with ACSF | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |
| High Value Plan | ADALIMUMAB-ADAZ  HADLIMA  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |
| Standard Opt Out Plan with ACSF | ADALIMUMAB-ADAZ  HYRIMOZ | CIMZIA, COSENTYX, ENBREL, KEVZARA, ORENCIA SQ/CLICK, OTEZLA, RINVOQ, SKYRIZI SUBCUTANEOUS, SOTYKTU, STELARA SUBCUTANEOUS, TALTZ, TREMFYA, XELJANZ, XELJANZ XR, ZEPOSIA |